Mark Yen

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 365 citations · Full text

Robust Central Reduction, Amyloid-β Peptide, Neurochemical Biomarkers +21

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

Marek Malík, E. Marcel van Gelderen, J H Lee et al. · Clinical Pharmacology & Therapeutics · 2012 · 147 citations

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease

Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum et al. · Journal of Neuroinflammation · 2017 · 93 citations · Full text

Domperidone, a new dopamine antagonist.

M C Champion, Michael N. Hartnett, Mark Yen · PubMed · 1986 · 78 citations · Full text

Molecular Pharmacology, Psychoactive Drug, Dopamine Agonist Agents +14

QT Interval Shortening With Isavuconazole:<i>In Vitro</i>and<i>In Vivo</i>Effects on Cardiac Repolarization

James J. Keirns, Amit Desai, Donna Kowalski et al. · Clinical Pharmacology & Therapeutics · 2017 · 73 citations · Full text